ARX Share Price Performance
AU$0
-0.63 (-100.00%)
Price AU$0
Fair ValueAU$0.83
Share Pricen/a
Aroa Biosurgery Limited Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 49 Fair Values set on narratives written by author
ARX Community Narratives
AN
Fair Value AU$0.83 21.4% undervalued intrinsic discount
CMS Reforms And International Expansion Will Drive US Healthcare Adoption
1users have liked this narrative
0users have commented on this narrative
32users have followed this narrative
CMS Reforms And International Expansion Will Drive US Healthcare Adoption
Key Takeaways New reimbursement policies and clinical milestones are set to boost product adoption, drive higher revenue, and improve margins through greater operating leverage. Strong market demand, underpenetrated existing accounts, and international expansion present significant long-term growth opportunities and diversified revenue streams.Read more
1users have liked this narrative
0users have commented on this narrative
32users have followed this narrative
AN
AU$0.83
21.4% undervalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue growth
16.96% p.a.
Profit Margin
8.38%
Future PE
33.72x
Share price in 2028
AU$1
Snowflake Analysis
Aroa Biosurgery Limited Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
Nov 24, 2025
- -0.011
- 85.73%
- -4.50%
- 0%
About ARX
- Founded
- 2007
- Employees
- n/a
- CEO
- WebsiteView website
Aroa Biosurgery Limited develops, manufactures, and sells medical devices for wound and soft tissue repair using extracellular matrix (ECM) technology in the United States and internationally. Its products include Endoform Natural and Endoform Antimicrobial Restorative Bioscaffold for treating acute and chronic wounds; Myriad Matrix, an engineered ECM for soft tissue repair, reinforcement, and complex wounds; Myriad Morcells, a morcellized (powdered) format of Myriad Matrix for soft tissue repair and complex wounds; Myriad Morcells Fine that delivers a bolus of biologically important ECM proteins to help kick start and sustain healing; and Symphony, a combination cellular and tissue product, indicated for the regeneration of functional tissue in complex wounds. The company also develops products for abdominal wall reconstruction, hernia repair, and breast reconstruction in North America and Europe. Aroa Biosurgery Limited was incorporated in 2007 and is headquartered in Auckland, New Zealand.
